When Semaglutide May Be Contraindicated Semaglutide is likely not appropriate for patients with active ulcerative colitis or those experiencing frequent flares
The trial also enabled up to 85.1 percent of participants to reduce their body weight by 5 percent, versus 38.8 percent with placebo
At 24 weeks, average weight loss was: At 48 weeks, average weight loss was: The study also found that, at 48 weeks, 100% of people taking 12mg lost at least 5% of their body weight , 93% lost at least 10% , and 83% lost at least 15%
Clinical trials demonstrate a dose-dependent relationship, with higher doses producing greater weight reductionup to 20.9% at 72 weeks with the 15 mg dose
A study has also modified the growth factor and prepared carboxymethyl CS recombinant human epidermal growth factor coupling (NaCMCh-rhEGF), which can protect rhEGF from degradation by protease and improve the application of the drug (Hajimiri et al., 2016)
Freezing reconstituted tirzepatide damages the peptide